January 11, 2007 -- Bristol-Myers Squibb partnered with fellow big pharma AstraZeneca to develop two type 2 diabetes compounds that BMS discovered in a deal worth up to $1.2 billion; Wyeth and Solvay entered into a follow-up neuroscience collaboration; Neuralstem out-licensed neural stem cell compounds; Ark Therapeutics will begin a Phase III test of Trinam; Entelos acquired an option on a Phase I selective progesterone-receptor modulator; Shire received European approval for enzyme replacement therapy Elaprase; and GenVec received approval to use endoscopic ultrasound administration in clinical trials of TNFerade. Riding the coattails of a very strong Q4 report from Genentech, the Centient Biotech 200™ rose 66 points to 4054, a jump of 1.66% and a near-record close. More details...
